Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study to Evaluate the Safety, Tolerability and Efficacy of Combination Therapy With SYS6090 Injection in Participants With Hepatocellular Carcinoma

NCT07761286 is registered in ClinicalTrials.gov with CSPC Megalith Biopharmaceutical Co.,Ltd. as lead sponsor.

NCT NCT07761286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07761286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study to Evaluate the Safety, Tolerability and Efficacy of Combination Therapy With SYS6090 Injection in Participants With Hepatocellular Carcinoma
Lead sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2031
Enrollment
288 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma